Global Cancer Monoclonal Antibodies Pipeline Analysis

November 2013 | 660 pages | ID: G4BD4A53785EN
PNS Pharma

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

In the past few years monoclonal antibodies have emerged as a therapeutic modality for cancer. These monoclonal antibodies are designed to selectively target cancer cells and extract various responses, thus indirectly protecting the non cancerous cells. This characteristic of monoclonal antibodies coupled with increasing potential of the oncology market has made many pharmaceutical giants to invest a significant portion of their R&D on cancer monoclonal antibodies.

In recent years the popularity of monoclonal antibodies has increase many folds as they have revolutionized the treatments for cancer. The applications of Monoclonal antibodies, which are administered intravenously, include cancer cell marking, growth signal blocking, the delivery of chemotherapy toxins, and the reduction of new blood vessel growth. The understanding of these treatments is rapidly becoming an indispensable part of biotech investing, and investors need to clearly understand how monoclonal antibodies are affecting the industry.

“Global Cancer Monoclonal Antibodies Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various Monoclonal Antibodies being developed for the treatment of Cancer. Research report covers all the ongoing Monoclonal Antibodies being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Cancer Monoclonal Antibodies market based upon development process. Following parameters for each Monoclonal Antibodies drug profile in development phase are covered in “Global Cancer Monoclonal Antibodies Pipeline Analysis” research report:

• Drug Profile Overview
• Alternate Names for Drug
• Active Indication
• Phase of Development
• Mechanism of Action
• Brand Name
• Orphan Designation
• Patent Information
• Country for Clinical Trial
• Owner / Originator/ Licensee/Collaborator
• Administrative Route
• Drug Class
• ATC Codes

Global Cancer Monoclonal Antibodies Drug Pipeline by Clinical Phase:

• Research: 68
• Preclinical: 240
• Phase-I: 112
• Phase-I/II: 29
• Phase-II: 73
• Phase-II/III: 5
• Phase-III: 31
• Preregistration: 3
• Marketed: 27

Contents

1. GLOBAL CANCER MONOCLONAL ANTIBODIES DRUG MARKET

2. CANCER MONOCLONAL ANTIBODIES DRUG CLINICAL PHASE: RESEARCH

2.1 Overview
2.2 Cancer Monoclonal Antibodies Drug Profile

3. CANCER MONOCLONAL ANTIBODIES DRUG CLINICAL PHASE: PRECLINICAL

3.1 Overview
3.2 Cancer Monoclonal Antibodies Drug Profile

4. CANCER MONOCLONAL ANTIBODIES DRUG CLINICAL PHASE: PHASE-I

4.1 Overview
4.2 Cancer Monoclonal Antibodies Drug Profile

5. CANCER MONOCLONAL ANTIBODIES DRUG CLINICAL PHASE: PHASE-I/II

5.1 Overview
5.2 Cancer Monoclonal Antibodies Drug Profile

6. CANCER MONOCLONAL ANTIBODIES DRUG CLINICAL PHASE: PHASE-II

6.1 Overview
6.2 Cancer Monoclonal Antibodies Drug Profile

7. CANCER MONOCLONAL ANTIBODIES DRUG CLINICAL PHASE: PHASE-II/III

7.1 Overview
7.2 Cancer Monoclonal Antibodies Drug Profile

8. CANCER MONOCLONAL ANTIBODIES DRUG CLINICAL PHASE: PHASE-III

8.1 Overview
8.2 Cancer Monoclonal Antibodies Drug Profile

9. CANCER MONOCLONAL ANTIBODIES DRUG CLINICAL PHASE: PREREGISTRATION

9.1 Overview
9.2 Cancer Monoclonal Antibodies Drug Profile

10. MARKETED

10.1 Overview
10.2 Marketed Cancer Monoclonal Antibodies Drug Profile

EACH DRUG PROFILE HAS TABLES REPRESENTING FOLLOWING INFORMATION:

Alternate Names
Originator & Owner
Collaborator
Technology Provider
Licensee
Highest Development Phase
Indications
Class
Mechanism of Action
ATC code
Designated Brand Name & Orphan Designation